RBC Capital Maintains Sector Perform on Design Therapeutics, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has maintained a 'Sector Perform' rating on Design Therapeutics (NASDAQ:DSGN) but has lowered the price target from $7 to $4.

November 14, 2023 | 4:52 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
RBC Capital's analyst has lowered the price target for Design Therapeutics from $7 to $4 but kept the rating at 'Sector Perform'.
The reduction in the price target by RBC Capital is likely to negatively impact investor sentiment towards DSGN in the short term, as it suggests a lower valuation than previously estimated. However, the maintenance of a 'Sector Perform' rating indicates that the analyst does not see significant underperformance relative to the sector, which may mitigate some negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100